Adaptimmune Therapeutics plc (473A) - Total Liabilities

Latest as of June 2025: €201.59 Million EUR ≈ $235.68 Million USD

Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) has total liabilities worth €201.59 Million EUR (≈ $235.68 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 473A net assets growth trend to track the company's year-over-year net asset growth rate.

Adaptimmune Therapeutics plc - Total Liabilities Trend (2016–2024)

This chart illustrates how Adaptimmune Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. See Adaptimmune Therapeutics plc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Adaptimmune Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Adaptimmune Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
OS Therapies Incorporated NYSE MKT:OSTX	USA	$4.25 Million
MeVis Medical Solutions AG XETRA:M3V	Germany	€8.06 Million
Oceanpal Inc NASDAQ:OP	USA	$4.10 Million
Shuang-Bang Industrial TWO:6506	Taiwan	NT$1.23 Billion
Minesto AB ST:MINEST	Sweden	Skr22.24 Million
Acuvi AB ST:ACUVI	Sweden	Skr124.00 Million
UBIVELOX Inc KQ:089850	Korea	₩289.69 Billion
Goodyear (Thailand) Public Company Limited BK:GYT	Thailand	฿5.19 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Adaptimmune Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 473A stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.52	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-2.84	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.54	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Adaptimmune Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Adaptimmune Therapeutics plc (2016–2024)

The table below shows the annual total liabilities of Adaptimmune Therapeutics plc from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	€234.11 Million ≈ $273.70 Million	-3.70%
2023-12-31	€243.10 Million ≈ $284.21 Million	-1.59%
2022-12-31	€247.04 Million ≈ $288.81 Million	-6.28%
2021-12-31	€263.58 Million ≈ $308.16 Million	+139.81%
2020-12-31	€109.92 Million ≈ $128.50 Million	+89.82%
2019-12-31	€57.91 Million ≈ $67.70 Million	+93.98%
2018-12-31	€29.85 Million ≈ $34.90 Million	-61.81%
2017-12-31	€78.16 Million ≈ $91.38 Million	+14.32%
2016-12-31	€68.37 Million ≈ $79.94 Million	--

About Adaptimmune Therapeutics plc

F:473A Germany

Market Cap

$50.20 Million

€42.94 Million EUR

Market Cap Rank

#22425 Global

#1982 in Germany

Share Price

€0.16

Change (1 day)

+6.58%

52-Week Range

€0.03 - €0.25

All Time High

€12.93